The Prostate Cancer Roundtable is a group of independent, patient-centric, not-for-profit organizations that cooperate to foster the development and implementation of a national policy agenda supporting high quality prostate cancer research, the prevention and early detection of clinically significant prostate cancer, the appropriate care and effective treatment of men with prostate cancer, and the appropriate education of all men at risk for this disease.
About 2.2 million men are now living in America after a diagnosis of prostate cancer … and about 30,000 die from prostate cancer every year.
Since 2008, the Prostate Cancer Roundtable has acted as a forum through which all members of the U.S. prostate cancer advocacy community can act in concert to ensure a shared set of policy and scientific priorities that affect the prevention, detection of risk, diagnosis, and management of prostate cancer. Our fundamental priorities are to ensure that, over time, we all work together on political, social, and policy priorities that will lead to a major decrease in the annual incidence of newly diagnosed cases of prostate cancer; the early diagnosis and optimal treatment of all cases of clinically significant prostate cancer; and access to high quality care for all men diagnosed with this disease. The Prostate Cancer Roundtable is convened by Men’s Health Network of Washington, DC.
Prostate cancer is the most prevalent form of cancer among American males. Approximately 230,000 men are diagnosed with prostate cancer each year, and about 30,000 will die from this disease. Any man may be at risk for prostate cancer, but increased risk factors are known to include race, family history, elevated prostate specific antigen (PSA) levels, positive findings on a digital rectal examination, exposure to Agent Orange and related chemicals, and selected pathological findings on prior biopsies.